7 results on '"Myriam Gandía Martínez"'
Search Results
2. P147 Is belimumab dose optimization possible in patients with systemic lupus erythematosus? Analysis of this therapeutic strategy in a large multicenter cohort of patients from Spanish rheumatology departments
- Author
-
Íñigo Rúa-Figueroa, Jose Maria Pego-Reigosa, Javier Narváez, Ivette Casafont-Solé, Eva Tomero, Clara Moriano, Elvira Díez Álvarez, María Jesús García-Villanueva, Consuelo Ramos Giráldez, Sandra Garrote, Maria Galindo Izquierdo, Jaime Calvo Alen, Beatriz Frade-Sosa, Irene Altabás-González, Andrea Hernández-Martín, Paola Vidal-Montal, Eleonora Penzo, Marta de la Rubia Navarro, José Andrés Román Ivorra, Raul Menor Almagro, Tarek Salman Montes, Norman Jimenez, Judit Font Urgelles, Carlos Marras Fernández, María Piqueras García, Julia Martínez Barrio, Marina Sánchez Lucas, Josefina Cortés Hernández, Myriam Gandía Martínez, Carmen Trapero Pérez, Alejandro Muñoz Jiménez, Juan Ramón de Dios, and Jos A Gómez-Puerta
- Subjects
Immunologic diseases. Allergy ,RC581-607 - Published
- 2024
- Full Text
- View/download PDF
3. Safety and Effectiveness of Abatacept in a Prospective Cohort of Patients with Rheumatoid Arthritis–Associated Interstitial Lung Disease
- Author
-
Natalia Mena-Vázquez, Marta Rojas-Gimenez, Clara Fuego-Varela, Aimara García-Studer, Nair Perez-Gómez, Carmen María Romero-Barco, Francisco Javier Godoy-Navarrete, Sara Manrique-Arija, Myriam Gandía-Martínez, Jerusalem Calvo-Gutiérrez, Pilar Morales-Garrido, Coral Mouriño-Rodriguez, Patricia Castro-Pérez, Isabel Añón-Oñate, Francisco Espildora, María Carmen Aguilar-Hurtado, Ana Hidalgo Conde, Rocío Arnedo Díez de los Ríos, Eva Cabrera César, Rocío Redondo-Rodriguez, María Luisa Velloso-Feijoo, and Antonio Fernández-Nebro
- Subjects
interstitial lung disease ,rheumatoid arthritis ,musculoskeletal diseases ,abatacept ,Medicine (miscellaneous) ,biologics ,respiratory system ,General Biochemistry, Genetics and Molecular Biology ,respiratory tract diseases - Abstract
Objective: To prospectively evaluate the safety and efficacy profile of abatacept in patients with rheumatoid arthritis–associated interstitial lung disease (RA-ILD). Methods: We performed a prospective observational multicenter study of a cohort of patients with RA-ILD treated with abatacept between 2015 and 2021. Patients were evaluated using high-resolution computed tomography and pulmonary function tests at initiation, 12 months, and the end of follow-up. The effectiveness of abatacept was evaluated based on whether ILD improved, stabilized, progressed, or was fatal. We also evaluated factors such as infection, hospitalization, and inflammatory activity using the 28-joint Disease Activity Score with the erythrocyte sedimentation rate (DAS28-ESR). Cox regression analysis was performed to identify factors associated with progression of lung disease. Results: The study population comprised 57 patients with RA-ILD treated with abatacept for a median (IQR) of 27.3 (12.2–42.8) months. Lung disease had progressed before starting abatacept in 45.6% of patients. At the end of follow-up, lung disease had improved or stabilized in 41 patients (71.9%) and worsened in 13 (22.8%); 3 patients (5.3%) died. No significant decreases were observed in forced vital capacity (FVC) or in the diffusing capacity of the lung for carbon monoxide (DLCO).The factors associated with progression of RA-ILD were baseline DAS28-ESR (OR [95% CI], 2.52 [1.03–3.12]; p = 0.041), FVC (OR [95% CI], 0.82 [0.70–0.96]; p = 0.019), and DLCO (OR [95% CI], 0.83 [0.72–0.96]; p = 0.018). Only 10.5% of patients experienced severe adverse effects. Conclusion: Pulmonary function and joint inflammation stabilized in 71% of patients with RA-ILD treated with abatacept. Abatacept had a favorable safety profile.
- Published
- 2022
- Full Text
- View/download PDF
4. Anti-TNF vs tocilizumab in refractory uveitic cystoid macular edema due to Behcet's disease. Multicenter study of 49 patients
- Author
-
Nuria Barroso-García, Belén Atienza-Mateo, Iván Ferraz-Amaro, Diana Prieto-Peña, Emma Beltrán, Alfredo Adán, Marisa Hernández-Garfella, Lucía Martínez-Costa, Miguel Cordero-Coma, Manuel Díaz-Llopis, José M. Herreras, Olga Maíz-Alonso, Ignacio Torre-Salaberri, Ana De Vicente-Delmás, David Díaz-Valle, Antonio Atanes-Sandoval, Félix Francisco, Santos Insua, Julio Sánchez, Raquel Almodóvar-González, Alejandro Jiménez-Sosa, Oscar Ruiz-Moreno, Myriam Gandía-Martínez, Joan M. Nolla, Vanesa Calvo-Río, Santos Castañeda, Miguel A. González-Gay, and Ricardo Blanco
- Subjects
Anesthesiology and Pain Medicine ,Rheumatology - Abstract
To compare the efficacy of TNF inhibitors (adalimumab (ADA) and infliximab (IFX)) vs tocilizumab (TCZ) in patients with refractory cystoid macular edema (CME) due to Behçet's disease (BD).Multicenter study of patients with BD-associated CME refractory to conventional and/or biological immunosuppressive drugs. From a cohort of 177 patients treated with anti-TNF and 14 patients treated with TCZ, we selected those with CME at baseline. We analyzed the evolution of macular thickness (main outcome), best-corrected visual acuity (BCVA) and intraocular inflammation (Tyndall and vitritis) from baseline up to 4 years in the 3 groups mentioned.49 patients and 72 eyes with CME were included. ADA was used in 25 patients (40 eyes), IFX in 15 (21 eyes) and TCZ in 9 (11 eyes). No statistically significant baseline differences were observed between the 3 groups except for a lower basal BCVA in TCZ group and a higher basal degree of intraocular inflammation in ADA group. Most patients from all groups had received several conventional immunosuppressive drugs. In addition, most patients in the group of TCZ had also received anti-TNF agents. Biological therapy was used in monotherapy (n=8) or combined with conventional immunosuppressive drugs (n=41). Macular thickness progressively decreased in the 3 groups, with no signs of CME after 1 year of treatment. Similarly, BCVA improvement and inflammatory intraocular remission was achieved in all groups.Refractory CME associated with BD uveitis can be effectively treated either with ADA, IFX or TCZ. Furthermore, TCZ is effective in patients resistant to anti-TNF therapy.
- Published
- 2023
5. Analysis of comorbidity in rheumatoid arthritis–associated interstitial lung disease: a nested case-cohort study
- Author
-
Natalia, Mena-Vázquez, Marta, Rojas-Gimenez, Carmen María, Romero-Barco, Myriam, Gandía-Martínez, Nair, Perez-Gómez, Francisco Javier, Godoy-Navarrete, Sara, Manrique-Arija, Aimara, Garcia-Studer, Jerusalem, Calvo-Gutiérrez, Clara Fuego, Varela, Pilar, Morales-Garrido, Patricia Castro, Pérez, Coral, Mouriño-Rodriguez, Isabel, Añón-Oñate, Francisco, Espildora, María Carmen, Aguilar-Hurtado, Rocío, Redondo, Ana Hidalgo, Conde, Rocío Arnedo Díez, de Los Ríos, Eva Cabrera, César, Maria Luisa, Velloso-Feijoo, and Antonio, Fernández-Nebro
- Subjects
Cohort Studies ,Arthritis, Rheumatoid ,Pharmacology ,C-Reactive Protein ,Humans ,Prospective Studies ,Comorbidity ,General Medicine ,Lung Diseases, Interstitial - Abstract
To describe comorbid conditions in patients with rheumatoid arthritis-associated interstitial lung disease (RA-ILD) and to analyze factors associated with multimorbidity.Nested case-cohort study of 2 prospective cohorts: one with RA-ILD (cases) and another with RA but not ILD (controls). The cohorts were matched for age, sex, and time since diagnosis. Multimorbidity was defined as the co-occurrence of 2 or more chronic diseases, in addition to RA and ILD. We evaluated the comorbid conditions included in the Charlson Comorbidity Index, cardiovascular risk factors, neuropsychiatric conditions, and other frequent conditions in RA. We also recorded clinical-laboratory variables, inflammatory activity according to the 28-joint Disease Activity Score, C-reactive protein (CRP), physical function, and pulmonary function. We performed 2 multivariate analyses to identify factors associated with multimorbidity in RA and RA-ILD.The final study population comprised 110 cases and 104 controls. Multimorbidity was more frequent among cases than controls (80 [72.7] vs 60 [57.7]; p = 0.021). In both groups, multimorbidity was associated with ILD (OR [95% CI] 1.92 [1.03-3.59]; p = 0.039), age (OR [95% CI] 1.05 [1.01-1.08]; p = 0.004), CRP (OR [95% CI] 1.16 [1.05-1.29]; p = 0.003), and erosions (OR [95% CI] 1.05 [1.01-1.08]; p = 0.004); in the cases, it was associated with CRP (OR [95% CI] 1.17 [1.01-1.35]; p = 0.027), anti-citrullinated peptide antibody (OR [95% CI] 1.23 [1.14-13.02]; p = 0.049), and forced vital capacity (OR [95% CI] 0.79 [0.96-0.99]; p = 0.036).In patients with RA, multimorbidity was associated with ILD, systemic inflammation, and advanced age.
- Published
- 2023
6. Rate of severe and fatal infections in a cohort of patients with interstitial lung disease associated with rheumatoid arthritis: a multicenter prospective study
- Author
-
Natalia Mena-Vázquez, Rocío Redondo-Rodriguez, Marta Rojas-Gimenez, Carmen María Romero-Barco, Clara Fuego-Varela, Nair Perez-Gómez, Isabel Añón-Oñate, Patricia Castro Pérez, Aimara García-Studer, Ana Hidalgo-Conde, Rocío Arnedo Díez de los Ríos, Eva Cabrera-César, Maria Luisa Velloso-Feijoo, Sara Manrique-Arija, Jerusalem Calvo-Gutiérrez, Myriam Gandía-Martínez, Pilar Morales-Garrido, Francisco Javier Godoy-Navarrete, Coral Mouriño-Rodriguez, Francisco Espildora, María Carmen Aguilar-Hurtado, and Antonio Fernández-Nebro
- Subjects
rheumatoid arthritis ,interstitial lung disease ,infection ,fatal infections microorganisms ,inflammation ,Immunologic diseases. Allergy ,RC581-607 - Abstract
ObjectiveTo describe severe infection, foci of infection, microorganisms, associated factors, and impact on mortality in patients with rheumatoid arthritis–associated interstitial lung disease (RA-ILD).Patients and methodsThe study was based on a multicenter prospective cohort of patients with RA-ILD followed up from 2015 to 2023. The main outcome measures were incident severe infection and fatal infection. We evaluated infectious foci, etiologic agents, vaccination status, variables associated with lung function, and clinical-therapeutic variables in RA. The incidence rate (IR) for infection and mortality was calculated per 100 person-years, and 3 multivariate models were constructed to explore factors associated with infection.ResultsWe followed up 148 patients with RA-ILD for a median 56.7 months (699.3 person-years). During this period, 142 patients (96%) had at least 1 infection. A total of 368 infectious episodes were recorded, with an IR of 52.6 per 100 person-years. Of the 48 patients who died, 65% did so from infection. Respiratory infections were the most common first infection (74%), infection overall (74%), and fatal infection (80%) and were caused mostly by SARS CoV-2, Streptococcus pneumoniae, Pseudomonas aeruginosa, and influenza A virus. The factors associated with an increased risk of infection and death in patients with RA-ILD were age, inflammatory activity, and therapy with corticosteroids and immunosuppressants.ConclusionPatients with RA-ILD have a high risk of serious infection, especially respiratory infection. Infection develops early, is recurrent, and is frequently fatal. The presence of associated factors such as advanced age, joint inflammation, and treatment highlight the importance of integrated and preventive medical care.
- Published
- 2024
- Full Text
- View/download PDF
7. LP-191 Baseline profile of systemic lupus erythematosus patients on treatment with belimumab of a Spanish multicenter cohort
- Author
-
Íñigo Rúa-Figueroa, Jose Maria Pego-Reigosa, José A Gómez-Puerta, Javier Narváez, Ivette Casafont-Solé, José Andrés Román-Ivorra, Raúl Menor-Almagro, Jaime Calvo-Alén, Eva Tomero, Julia Martínez-Barrio, María Galindo-Izquierdo, Clara Moriano, Josefina Cortés-Hernández, María Jesús García-Villanueva, Elvira Díez-Álvarez, Irene Altabás-González, Coral Mouriño-Rodriguez, Norman Jiménez-Otero, Andrea Hernández-Martín, Judit Font-Urgelles, Marta De La Rubia-Navarro, Tarek Salman-Montes, Paola Vidal-Montal, Sandra Garrote-Corral, María Ángeles Blázquez-Cañamero, Carlos Marras-Fernández, María Piqueras-García, Marina Sánchez-Lucas, Eleonora Penzo, Juan Ramón De Dios Jiménez De Aberásturi, Belén Álvarez-Rodríguez, Margarida Vasques-Rocha, Myriam Gandía-Martínez, Consuelo Ramos-Giráldez, Carmen Trapero-Pérez, and Alejandro Muñoz-Jiménez
- Subjects
Immunologic diseases. Allergy ,RC581-607 - Published
- 2023
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.